These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9524060)

  • 1. An active zymogen: unravelling the mystery of tissue-type plasminogen activator.
    Stubbs MT; Renatus M; Bode W
    Biol Chem; 1998 Feb; 379(2):95-103. PubMed ID: 9524060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA.
    Renatus M; Engh RA; Stubbs MT; Huber R; Fischer S; Kohnert U; Bode W
    EMBO J; 1997 Aug; 16(16):4797-805. PubMed ID: 9305622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Converting tissue plasminogen activator to a zymogen: a regulatory triad of Asp-His-Ser.
    Madison EL; Kobe A; Gething MJ; Sambrook JF; Goldsmith EJ
    Science; 1993 Oct; 262(5132):419-21. PubMed ID: 8211162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants of tissue-type plasminogen activator which display substantially enhanced stimulation by fibrin.
    Tachias K; Madison EL
    J Biol Chem; 1995 Aug; 270(31):18319-22. PubMed ID: 7629153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
    Bakker AH; Nieuwenbroek NM; Verheijen JH
    Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural features mediating fibrin selectivity of vampire bat plasminogen activators.
    Bringmann P; Gruber D; Liese A; Toschi L; Krätzchmar J; Schleuning WD; Donner P
    J Biol Chem; 1995 Oct; 270(43):25596-603. PubMed ID: 7592732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-type plasminogen activator: variants and crystal/solution structures demarcate structural determinants of function.
    Bode W; Renatus M
    Curr Opin Struct Biol; 1997 Dec; 7(6):865-72. PubMed ID: 9434908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variants of tissue-type plasminogen activator with substantially enhanced response and selectivity toward fibrin co-factors.
    Strandberg L; Madison EL
    J Biol Chem; 1995 Oct; 270(40):23444-9. PubMed ID: 7559505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced fibrinolysis by proteolysed coagulation factor Xa.
    Talbot K; Meixner SC; Pryzdial EL
    Biochim Biophys Acta; 2010 Apr; 1804(4):723-30. PubMed ID: 19931652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of fibrin binding on the biochemical properties of single-chain tissue-type plasminogen activator (t-PA) and single-chain chimeric plasminogen activator (t-PA/scu-PA).
    Fischer BE
    Blood Coagul Fibrinolysis; 1992 Feb; 3(1):39-46. PubMed ID: 1320415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator. A kinetic analysis.
    Bergum PW; Gardell SJ
    J Biol Chem; 1992 Sep; 267(25):17726-31. PubMed ID: 1387641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of initiation of fibrinolysis by fibrin.
    Medved L; Nieuwenhuizen W
    Thromb Haemost; 2003 Mar; 89(3):409-19. PubMed ID: 12624622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis.
    Tate KM; Higgins DL; Holmes WE; Winkler ME; Heyneker HL; Vehar GA
    Biochemistry; 1987 Jan; 26(2):338-43. PubMed ID: 3103680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator.
    Gardell SJ; Hare TR; Bergum PW; Cuca GC; O'Neill-Palladino L; Zavodny SM
    Blood; 1990 Dec; 76(12):2560-4. PubMed ID: 2124935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator.
    Gardell SJ; Duong LT; Diehl RE; York JD; Hare TR; Register RB; Jacobs JW; Dixon RA; Friedman PA
    J Biol Chem; 1989 Oct; 264(30):17947-52. PubMed ID: 2509450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the one-chain to two-chain conversion in tissue plasminogen activator: characterization of mutations at position 275.
    Higgins DL; Lamb MC; Young SL; Powers DB; Anderson S
    Thromb Res; 1990 Feb; 57(4):527-39. PubMed ID: 2139248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Converting tissue type plasminogen activator into a zymogen. Important role of Lys156.
    Tachias K; Madison EL
    J Biol Chem; 1997 Jan; 272(1):28-31. PubMed ID: 8995220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage.
    Renatus M; Stubbs MT; Huber R; Bringmann P; Donner P; Schleuning WD; Bode W
    Biochemistry; 1997 Nov; 36(44):13483-93. PubMed ID: 9354616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of tissue plasminogen activator to endothelial cells. The effect on functional properties. Localization of a ligand in the B-chain of tPA.
    Cheng XF; Brohlin M; Pohl G; Bäck O; Wallén P
    Thromb Res; 1995 Jan; 77(2):149-64. PubMed ID: 7740507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.
    Urano S; Metzger AR; Castellino FJ
    Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2568-71. PubMed ID: 2523073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.